Population pharmacokinetics of lamotrigine in patients with epilepsy

被引:2
作者
Milovanovic, J. R. [1 ]
Jankovic, S. M. [1 ]
机构
[1] Univ Kragujevac, Fac Med, Dept Pharmacol, Kragujevac 34000, Serbia
关键词
lamotrigine; epilepsy; NONMEM; population pharmacokinetics; therapeutic drug monitoring; ANTIEPILEPTIC DRUGS; SERUM CONCENTRATIONS; COMBINATION THERAPY; MONOTHERAPY; CHILDREN; AGE; ADOLESCENTS; TOPIRAMATE; CLEARANCE; EFFICACY;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The purpose of this study was to derive a population pharmacokinetics (PPK) model of lamotrigine clearance as well as to identify and describe factors that influence it in Serbian patients with epilepsy. Methods: A total of 40 steady-state serum concentrations from 38 adult and pediatric patients with epilepsy, collected during routine therapeutic drug monitoring, were used for the analysis. To determine the influence of different covariates on the estimate of lamotrigine clearance we built a non-linear mixed-effects one-compartment model with the first order elimination and without absorption. Results: Typical mean value of lamotrigine clearance, estimated by the base model (without covariates), in our population was 1.15 l h(-1). The final model showed that lamotrigine clearance increased with total body weight, daily dose and concomitant administration of carbamazepine, and decreased with concomitant administration of valproate. The magnitude of carbamazepine and valproate effect was +1.13 l h(-1) and -1 l h(-1), respectively. The final model was validated in a group of 15 epileptic patients, showing good predictive performance. Conclusions: The derived model describes well lamotrigine clearance in terms of characteristics of Serbian patients, offering basis for rational individualization of lamotrigine closing regimens.
引用
收藏
页码:752 / 760
页数:9
相关论文
共 44 条
  • [1] Inherent correlation between dose and clearance in therapeutic drug monitoring settings: Possible misinterpretation in population pharmacokinetic analyses
    Ahn, JE
    Birnbaum, AK
    Brundage, RC
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2005, 32 (5-6) : 703 - 718
  • [2] Lamotrigine serum concentration-to-dose ratio: Influence of age and concomitant antiepileptic drugs and dosage implications
    Armijo, JA
    Bravo, J
    Cuadrado, A
    Herranz, JL
    [J]. THERAPEUTIC DRUG MONITORING, 1999, 21 (02) : 182 - 190
  • [3] Lamotrigine plasma concentrations in children and adults: Influence of age and associated therapy
    Battino, D
    Croci, D
    Granata, T
    Estienne, M
    Pisani, F
    Avanzini, G
    [J]. THERAPEUTIC DRUG MONITORING, 1997, 19 (06) : 620 - 627
  • [4] Beal S L., 1998, NONMEM Users Guides
  • [5] Lack of an effect of topiramate on lamotrigine serum concentrations
    Berry, DJ
    Besag, FMC
    Pool, F
    Natarajan, J
    Doose, D
    [J]. EPILEPSIA, 2002, 43 (08) : 818 - 823
  • [6] Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy
    Biton, Victor
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (06) : 1009 - 1018
  • [7] Lamotrigine in clinical practice: Long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center
    Bootsma, H. P. R.
    Vos, A. M.
    Hulsman, J.
    Lambrechts, D.
    Leenen, L.
    Majoie, M.
    Savelkoul, M.
    Schellekens, A.
    Aldenkamp, A. P.
    [J]. EPILEPSY & BEHAVIOR, 2008, 12 (02) : 262 - 268
  • [8] Lamotrigine substitution study: Evidence for synergism with sodium valproate?
    Brodie, MJ
    Yuen, AWC
    [J]. EPILEPSY RESEARCH, 1997, 26 (03) : 423 - 432
  • [9] Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children
    Chen, C
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (02) : 135 - 145
  • [10] Chong E, 2002, ANN PHARMACOTHER, V36, P917